Molecular diagnostics platform
Biocartis SA
Incorporated
02.07.2007Headquarters
LausanneSupport
Molecular diagnostics is presently a time-consuming process suited only for large laboratories. Biocartis is now bringing this analytical technology to smaller labs and hospitals with a simple and cost-effective technology. With it, illnesses ranging from infections to cancer can be detected earlier, faster and more reliably. This not only improves the chances of a cure but also reduces health care costs.
www.biocartis.com
News
Biocartis raises EUR100 million in successful public offering (startupticker.ch)
Biocartis launches its flagship diagnostics platform Idylla (startupticker.ch)
Biocartis raises EUR 64.5 million plus EUR 15 million for a new spin-off (startupticker.ch)
Biocartis and Abbott Announce Exclusive Partnership (startupticker.ch)
Biocartis raises EUR 30 million and prepares for market entry (startupticker.ch)
Market launch of Biocartis‘ diagnostic platform is on the horizon (startupticker.ch)
Biocartis and Hospital del Mar develop diagnostic colon cancer test (startupticker.ch)
Biocartis completes CHF42million Series D Fund Raising (startupticker.ch)
Debiopharm, Immunexpress and Biocartis Announce Collaboration (startupticker.ch)
Biocartis collaborates with Philips and Wellcome Trust (startupticker.ch)
Biocartis completes EUR 71 million financing round (startupticker.ch)
Milestones news
Biocartis acquires Philips Technology Platform for Automated DNA/RNA Molecular Diagnostic Testing
